FluoroPharma Reports Positive Results of Cardiac Imaging Tracer
Posted on: Tuesday, 4 March 2008, 06:00 CST
FluoroPharma has reported positive Phase I safety results for CardioPET, the company's novel cardiac imaging product.
The trial was designed to evaluate safety, distribution and dosimetry of CardioPET as a PET tracer for myocardial imaging in healthy subjects and patients with coronary artery disease (CAD).
According to Alan Fischman, principal investigator of the study, the CardioPET device performed well in both healthy volunteers and patients with CAD. It also achieved all safety endpoints and experienced no safety issues.
CardioPET allows assessment of acute and chronic coronary artery disease while patients are at rest. FluoroPharma anticipates that CardioPET may be an accurate alternative to standard treadmill stress-testing and for patients that are unable to exercise.
Source: Datamonitor
Related Articles
- Industry Recognized and Trusted Leader, Bruce Matter, Joins Healthcare IT Company, Peminic, Inc. as Company Growth in the Areas of Patient Safety, Risk Management, and Patient Satisfaction Accelerates
- Leaders at Henry Ford Health System and Memorial Hermann Healthcare System Awarded for Commitment to Creating Safer, More Transparent Environments for Patients
- Legislation Promotes Healthcare IT Infrastructure and Patient Data Safety Across Europe
- NRC+Picker Highlights Safe Medication Administration During National Patient Safety Week
- Less Ads, More Data Urged for Drug Safety
- Experts Say Patients, Doctors Need Clearer Data
- Anthem Blue Cross and Blue Shield in Virginia Awards $12 Million to 41 Hospitals for Advances in Patient Care and Safety
- Preston Hospital Promotes Patient Safety This Week
- Ashe Memorial Hospital Embraces Omnicell End-to-End Medication-Use Technology Solution to Improve Patient Safety
- LiveData OR Dashboard Goes ''Live'' at Massachusetts General Hospital; Visually Integrated Operating Room Will Enhance Patient Safety
 |
 |
User Comments (0)
RSS Feeds